Ongoing prothrombotic state in patients with antiphospholipid antibodies:: A role for increased lipid peroxidation

被引:68
作者
Praticò, D
Ferro, D
Iuliano, L
Rokach, J
Conti, F
Valesini, G
FitzGerald, GA
Violi, F [1 ]
机构
[1] Univ La Sapienza, Inst Clin Med 1, I-00185 Rome, Italy
[2] Univ Penn, Ctr Expt Therapeut, Philadelphia, PA 19104 USA
关键词
D O I
10.1182/blood.V93.10.3401.410k36_3401_3407
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We measured the urinary excretion of Isoprostane F-2 alpha-III and Isoprostane-F-2 alpha-VI, two markers of in vivo lipid peroxidation, and the circulating levels of the prothrombin fragment F1+2, a marker of thrombin generation, in 18 antiphospholipid antibodies-positive patients, in 18 antiphospholipid antibodies-negative patients with systemic lupus erythematosus, and in 20 healthy subjects. Furthermore, 12 patients positive for antiphospholipid antibodies were treated with (n = 7) or without (n = 5) antioxidant vitamins (vitamin E at 900 IU/d and vitamin C at 2,000 mg/d) for 4 weeks. Compared with antiphospholipid antibodies-negative patients, antiphospholipid antibodies-positive patients had higher urinary values of Isoprostane-F-2 alpha-III (P =.0001), Isoprostane-F-2 alpha-VI (P = .006), and plasma levels of the prothrombin fragment F1+2 (P =.0001). In antiphospholipid-positive patients, F1+2 significantly correlated with Isoprostane-F-2 alpha-III (Rho =.56, P =.017) and Isoprostane-F-2 alpha-VI (Rho =.61, P =.008). After 4 weeks of supplementation with antioxidant vitamins, we found a significant decrease in F1+2 levels (P <.005) concomitantly with a significant reduction of both Isoprostane-F-2 alpha-III (P =.007) and Isoprostane-F-2 alpha-VI (P <.005), No change of these variables was observed in patients not receiving antioxidant treatment. This study suggests that lipid peroxidation might contribute to the activation of clotting system in patients positive for antiphospholipid antibodies. (C) 1999 by The American Society of Hematology.
引用
收藏
页码:3401 / 3407
页数:7
相关论文
共 32 条
[1]  
Armitage P, 1990, STAT METHODS MED RES
[2]   POSTTRANSCRIPTIONAL REGULATION OF MACROPHAGE TISSUE FACTOR EXPRESSION BY ANTIOXIDANTS [J].
BRISSEAU, GF ;
DACKIW, APB ;
CHEUNG, PYC ;
CHRISTIE, N ;
ROTSTEIN, OD .
BLOOD, 1995, 85 (04) :1025-1035
[3]   Total plasma antioxidant capacity predicts thrombosis-prone status in NIDDM patients [J].
Ceriello, A ;
Bortolotti, N ;
Pirisi, M ;
Crescentini, A ;
Tonutti, L ;
Motz, E ;
Russo, A ;
Giacomello, R ;
Stel, G ;
Taboga, C .
DIABETES CARE, 1997, 20 (10) :1589-1593
[4]   COPPER-INDUCED TISSUE FACTOR EXPRESSION IN HUMAN MONOCYTIC THP-1 CELLS AND ITS INHIBITION BY ANTIOXIDANTS [J].
CRUTCHLEY, DJ ;
QUE, BG .
CIRCULATION, 1995, 92 (02) :238-243
[5]   8-Epi PGF(2 alpha) generation during coronary reperfusion - A potential quantitative marker of oxidant stress in vivo [J].
Delanty, N ;
Reilly, MP ;
Pratico, D ;
Lawson, JA ;
McCarthy, JF ;
Wood, AE ;
Ohnishi, ST ;
Fitzgerald, DJ ;
FitzGerald, GA .
CIRCULATION, 1997, 95 (11) :2492-2499
[6]  
Ferro D, 1997, CIRCULATION, V95, P1425
[7]   METHODS FOR DETECTING LUPUS ANTICOAGULANTS AND THEIR RELATION TO THROMBOSIS AND MISCARRIAGE IN PATIENTS WITH SYSTEMIC LUPUS-ERYTHEMATOSUS [J].
FERRO, D ;
SALIOLA, M ;
QUINTARELLI, C ;
VALESINI, G ;
BASILI, S ;
GRANDILLI, AM ;
BONAVITA, MS ;
VIOLI, F .
JOURNAL OF CLINICAL PATHOLOGY, 1992, 45 (04) :332-338
[8]   LUPUS ANTICOAGULANT AND INCREASED THROMBIN GENERATION IN PATIENTS WITH SYSTEMIC LUPUS-ERYTHEMATOSUS [J].
FERRO, D ;
QUINTARELLI, C ;
VALESINI, G ;
VIOLI, F .
BLOOD, 1994, 83 (01) :304-304
[9]  
GINSBERG JS, 1993, BLOOD, V81, P2958
[10]  
HAMSTEN A, 1986, LANCET, V1, P113